[
  {
    "ts": null,
    "headline": "Abbott: GLP-1 Beneficiary - A Dividend Raise May Be Coming",
    "summary": "Abbottâs FY2025 guidance shows robust growth driven by diabetes care, new product launches, and strong demand. Find out why ABT stock is a buy.",
    "url": "https://finnhub.io/api/news?id=4364a4daaa4a5f20af9cb9252a98f1e8cfbfde018b64b24811dce6b052dd81dd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760780359,
      "headline": "Abbott: GLP-1 Beneficiary - A Dividend Raise May Be Coming",
      "id": 137134159,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2200929852/image_2200929852.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Abbottâs FY2025 guidance shows robust growth driven by diabetes care, new product launches, and strong demand. Find out why ABT stock is a buy.",
      "url": "https://finnhub.io/api/news?id=4364a4daaa4a5f20af9cb9252a98f1e8cfbfde018b64b24811dce6b052dd81dd"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Maintains Abbott Laboratories (ABT) Overweight Recommendation",
    "summary": "Barclays Maintains Abbott Laboratories (ABT) Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=8cd608ccae0faa35429c970d39c332e0569f356d5ced51ad28294adbdb8982c0",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760746057,
      "headline": "Barclays Maintains Abbott Laboratories (ABT) Overweight Recommendation",
      "id": 137130525,
      "image": "",
      "related": "ABT",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8cd608ccae0faa35429c970d39c332e0569f356d5ced51ad28294adbdb8982c0"
    }
  }
]